Clinical trials
Acute Myeloid Leukemia in Remission clinical trials
Below are recruiting acute myeloid leukemia in remission clinical trials, each written for real people, not researchers. We’re tracking 186 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT00801489RecruitingPhase 2
New treatment for AML or high-risk MDS using combination chemo
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
Houston, TexasAges 18 years+ - NCT02727803RecruitingPhase 2
Personalized natural killer cell therapy for blood cancers
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Houston, TexasAges 15–80 - NCT02508038RecruitingPhase 1
Test CD19+ depleted donor transplant for hard childhood cancers
This Phase 1 study tests a special type of half-matched (haploidentical) stem cell transplant plus medicines, aiming to reduce cancer relapse after transplant. It may help children and teens with certain leukemia/lymphoma or specific solid tumors who do not have a fully matched donor or whose best options are limited.
Madison, WisconsinAges 7 months–21 years - NCT03314974RecruitingPhase 2
Stem cell transplant study for blood cancers
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
Minneapolis, MinnesotaAges Up to 60 years - NCT02646839Enrolling by invitationPhase 2
Testing a gene-matched transplant approach for childhood leukemia
This trial studies a specific type of partially matched (haploidentical) stem cell transplant in children with ALL, AML, or MDS. It looks at whether using certain immune system gene patterns (KIR) and measuring leftover disease after treatment can improve outcomes and cost-effectiveness.
Los Angeles, CaliforniaAges Up to 21 years - NCT07493538RecruitingPhase 2
Blood stem cell transplant with lower-intensity chemo for blood cancers
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
Minneapolis, MinnesotaAges 2–75 - NCT07563179RecruitingPhase 2
Bugitinib with Venetoclax and Cytarabine for Relapsed AML
This trial tests a combination of three drugs (bugitinib, venetoclax, and cytarabine) for patients with acute myeloid leukemia (AML) that has returned or didn't respond to prior treatments. The goal is to see if this combination can help patients achieve remission and improve survival.
Shenzhen, GuangdongAges 18–70 - NCT07566585RecruitingPhase 1
Safety study of BSB-2002 for relapsed or refractory AML with NPM1 mutation
This is a Phase 1 trial testing a new drug called BSB-2002 in patients with acute myeloid leukemia (AML) that has come back or stopped responding to previous treatments. The drug is designed specifically for patients whose cancer cells have a particular genetic change (NPM1 mutation) and may help control the cancer by activating the immune system.
St Louis, MissouriAges 18 years+ - NCT07668557RecruitingPhase 1
CLL1-CD33 CAR-T cells for relapsed or refractory acute myeloid leukemia
This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.
Nanchang, JiangxiAges 18–70 - NCT07672262RecruitingPhase 2
VA maintenance before transplant for intermediate-risk AML
This trial tests whether giving Venetoclax and Azacitidine (VA) after your first remission helps keep you in remission before a stem cell transplant. It's for people with intermediate-risk AML who are planning to have a donor transplant.
Suzhou, JiangsuAges 18 years+ - NCT07566377RecruitingPhase 2
Cord Blood Transplant for Children and Young Adults With Blood Cancer
This study tests whether using cord blood stem cells (collected from umbilical cords after birth) can help treat high-risk blood cancers in children and young adults when a matched donor is not quickly available. Cord blood transplants may help prevent cancer from coming back.
New York, New YorkAges Up to 26 years - NCT06803745Recruiting
Comparing two radiation doses for leukemia transplant
This trial tests whether a lower or higher dose of total body irradiation works better for people with acute leukemia getting a stem cell transplant for the first time. It aims to find the safest and most effective radiation level to prepare your body for the transplant.
Baltimore, MarylandAges Any age - NCT06144606RecruitingPhase 2
KTE-X19 CAR T for MRD+ B-ALL
This trial tests a CAR T-cell therapy called KTE-X19 for people with B-cell ALL that is in remission but still has trace disease (MRD-positive). The goal is to see if this treatment can eliminate the remaining cancer cells and prevent relapse.
Tampa, FloridaAges 18 years+ - NCT06313437RecruitingPhase 1
Revumenib with 7+3 and midostaurin for AML
This trial tests a new drug called revumenib combined with a strong chemotherapy regimen (7+3) and midostaurin for people with newly diagnosed AML that has specific gene mutations (FLT3 and NPM1). The goal is to see if this combination works better than standard treatments.
New Haven, ConnecticutAges 18–75 - NCT06232694Recruiting
Combination therapy for newly diagnosed AML
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
Nanjing, JiangsuAges 18–60 - NCT07392970RecruitingPhase 2
Motixafortide to improve AML treatment response after chemo
This trial tests if adding motixafortide can help find and eliminate leftover leukemia cells in people with AML who are in remission after initial chemotherapy. The goal is to make remission deeper and more durable.
St Louis, MissouriAges 18 years+ - NCT07250646RecruitingPhase 1
Rebecsinib for secondary AML or high-risk myelofibrosis
This trial tests a new drug called rebecsinib for people with a certain type of leukemia (secondary acute myeloid leukemia) or a high-risk bone marrow disorder (myelofibrosis) that has come back or not responded to other treatments. The goal is to see if it works and is safe.
Duarte, CaliforniaAges 18 years+ - NCT02416388RecruitingPhase 2/Phase 3
Trial for AML treatments and preventing graft-versus-host disease
This trial tests different chemotherapy induction, consolidation (follow-up treatment), and strategies to prevent complications after an allogeneic stem cell transplant. It aims to improve overall survival and reduce serious transplant side effects like graft-versus-host disease (GVHD).
AmiensAges 18–61 - NCT03728335RecruitingPhase 2
Enasidenib maintenance after transplant for IDH2-mutated AML
This trial studies enasidenib to help keep acute myeloid leukemia (AML) under control after an allogeneic stem cell transplant in people with an IDH2 mutation. It may help reduce the chance of the leukemia coming back by targeting the mutation that drives the disease.
Duarte, CaliforniaAges 18 years+ - NCT03828773Recruiting
Azole antifungal prevention for leukemia during low white blood counts
This trial tests whether using a targeted antifungal medicine (aimed at PTX3) can better prevent serious fungal infections in adults with AML or a related bone marrow disease who will have very low neutrophils. It may help lower the risk of dangerous infections during intensive chemotherapy hospital stays.
Ghent, BelgiumAges 18 years+ - NCT05334693RecruitingPhase 1/Phase 2
Donor immune cells to help prevent AML return after treatment
This study tests an “immune cell therapy” made from a family donor to help children and young adults with AML stay in remission after chemotherapy. It may help reduce the chance that AML comes back, but eligibility depends on remission status, donor suitability, and avoiding certain infections or liver issues.
Minsk, Minsk OblastAges 6 months–21 years - NCT05431257RecruitingPhase 2
Azacitidine plus venetoclax for older or unfit AML
This Phase 2 study tests whether the combination of azacitidine and venetoclax can help people with acute myeloid leukemia (AML) who can’t handle standard intensive chemotherapy, including some relapsed or refractory cases. It also involves extra optional-style lab testing on your leukemia (bio-banking and “-omics” profiling) to learn which drug sensitivities may matter.
CopenhagenAges 18 years+ - NCT05682755RecruitingPhase 1/Phase 2
Chidamide to Prevent AML Return After Bone Marrow Transplant
This Phase 1/2 study tests whether chidamide can help prevent high-risk acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow transplant (allo-HSCT). Participants must already be in complete remission and have recovered blood counts after transplant.
Chengdu, SichuanAges 18–65 - NCT05858814RecruitingPhase 1/Phase 2
Cell therapy to help prevent AML relapse after transplant
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
Hefei, AnhuiAges 18–70
Hear when a new Acute Myeloid Leukemia in Remission trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute myeloid leukemia in remission?
- Yes. Clin2 currently lists 186 recruiting acute myeloid leukemia in remission studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute myeloid leukemia in remission trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute myeloid leukemia in remission trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.